blood cells. As such, these changes are likely to be acquired during neoplastic transformation. From the available evidence, the effect of these epigenetic changes on basal and/or inducible expression of VHL, and on clinico-pathological parameters, cannot be determined. Studies to address these questions and to assess epigenetic change in VHL in large numbers of AML and MDS cases, using bisulphite sequencing, are in progress.
Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis Leukemia (2008) 22, 1295-1298; doi:10.1038/sj.leu.2405054; published online 6 December 2007 Myelodysplastic/myeloproliferative disease-unclassifiable (MDS/ MPD-U) is a newly defined clinical entity in the World Health Organization (WHO) classification. 1 It includes cases with features of both myelodysplasia and myeloproliferation that do not meet the criteria for any of the other MDS or MPD entities. In addition, it includes a provisional subentity refractory anemia with ringed sideroblasts and marked thrombocytosis (RARS-T). Recent studies have shown an increased incidence of JAK2 V617F mutation in patients with RARS-T, suggesting a different biological behavior. [2] [3] [4] [5] Our aim was to describe the clinical outcome of MDS/MPD-U patients and, in particular RARS-T patients, who harbor the JAK2 V617F mutation. To identify patients with MDS/MPD-U and RARS-T, we reviewed all patients in the database of the Department of Leukemia at the University of Texas MD Anderson Cancer Center, seen initially between September 1987 and July 2006, with a recorded diagnosis of either MDS/MPD, chronic myeloproliferative disease-unclassifiable or refractory anemia with ringed sideroblasts (RARS) that had platelets4600 Â 10 9 l
À1
. All cases were reviewed independently by two expert hematopathologists and diagnoses were modified, when appropriate, according to the WHO criteria. The diagnosis of MDS/MPD-U was considered if the case had clinical, laboratory and morphological features of MDS (including erythroid dysplasia) with o20% blasts in the blood and bone marrow, with no history of MDS or MPD, with prominent MPD features (for example, platelets4600 Â 10 9 l À1 or WBC413 Â 10 9 l
, with or without splenomegaly), no recent cytotoxic therapy or growth factor use, no del(5q), t(3;3)(q21;q26) or inv(3) (q21q26) cytogenetic abnormalities, or the case had mixed MDS and MPD features but could not be assigned to any other category. To be further subclassified as RARS-T, the case had to include refractory anemia, ringed sideroblasts and platelets4 600 Â 10 9 l
. For the purpose of this study, therefore, the term 'MDS/MPD-U' refers to patients with the diagnosis of MDS/ MPD-U that do not belong to the subtype RARS-T (they are evaluated separately).
This study was approved by the Institutional Review Board. JAK2 V617F mutational status was assessed using standard PCR technique, using DNA extracted from paraffin-embedded bone marrow core biopsies. Primers included JAK2-Exon14-F (5 0 -GGACCAAAGCACATTGTATCCTC-3 0 ) and JAK2-Exon14-R (5 0 -GGGCATTGTAACCTTCTACTT). The resulting 400 bp JAK2
PCR product was purified using the Qiagen PCR Purification Kit (Qiagen, Valencia, CA, USA). Quantitative allele-specific suppressive PCR (ASS-PCR) was then performed using the purified 400 bp PCR product on a sequence detection system 7000 platform (Applied Biosystems, Foster City, CA, USA), as previously described. 6 Survival was analyzed by the KaplanMeier method and compared using the log-rank test. Categorical values were compared using Pearson's w 2 test. Sixteen patients with a diagnosis of RARS-T and 28 with MDS/ MPD-U, according to the WHO criteria, were identified. The clinical, hematologic, cytogenetic and molecular features are summarized in Table 1 . Overall, five patients had prior malignancy, of which two received radiation therapy, but none had received prior chemotherapy. As expected, the median platelet count was significantly higher in RARS-T than in MDS/ MPD-U, but there was no significant difference in WBC count or hemoglobin level. Cytogenetic analysis was performed on all patients except one with RARS-T. Of the RARS-T patients, one had trisomy 8 and the rest had diploid cytogenetics. Of the MDS/MPD-U patients, 10 (36%) had diploid cytogenetics, 5 had complex cytogenetics (X3 abnormalities), 4 had trisomy 8, 2 had 5qÀ associated with other abnormalities (one with del(12)(p11.2) and one with t(2;11)(p21;q23)) and the rest had miscellaneous abnormalities. JAK2 V617F mutation analysis was performed on 40 bone marrow samples; it was positive in 10 (38%) MDS/MPD-U patients and 5 (36%) RARS-T patients.
Other studies have reported a lower incidence of JAK2 mutation in patients with MDS/MPD-U; 5 it is possible that this difference stems from the small number of patients studied or from the sensitivity of the techniques used. Interestingly, all patients with RARS-T who harbored the JAK2 V617F mutation were heterozygous for the mutation. There was no difference in baseline patient characteristics with regard to age, platelet count, hemoglobin level, WBC count or cytogenetics between patients with or without the JAK2 mutation. Similarly, there was no difference when comparing patients with or without the JAK2 mutation within each subgroup, that is, RARS-T and MDS/MPD-U.
Within the RARS-T group, JAK2 V617F-positive patients had better median survival (MS) than JAK2 V617F-negative patients (not reached vs 80 months; P ¼ 0.057). Other patients' characteristics of significance (age, WBC count, hemoglobin, cytogenetic abnormality) did not have an impact on survival.
Within the MDS/MPD-U group, MS of JAK2 V617F-positive and -negative patients was not significantly different (32 vs 12 months; P ¼ 0.44). Of the 28 MDS/MPD-U patients, 9 had thrombocytosis (platelets4450 Â 10 9 l À1 ) and their MS has not been reached, while it was 12 months for all others (Po0.001). Of those nine patients, five were JAK2 V617F positive, and five had abnormal cytogenetics. Age, WBC count, hemoglobin and abnormal cytogenetics did not have an impact on survival.
Overall, patients with abnormal cytogenetics (n ¼ 19) had poorer MS than patients with diploid cytogenetics (n ¼ 24) (19 months vs not reached; P ¼ 0.0098). Since a great majority of MDS/MPD-U patients had abnormal cytogenetics, it is not surprising that their MS was inferior to that of RARS-T patients (19 months vs not reached; P ¼ 0.003; Figure 1a ). However, MS of patients with RARS-T with diploid cytogenetics was significantly better than that of MDS/MPD-U patients and diploid cytogenetics (MS not reached vs 32 months, respectively; P ¼ 0.021).
Overall, JAK2 V617F-positive patients (n ¼ 15) had MS of 82 months vs 52 months for JAK2 V617F-negative patients (n ¼ 25; P ¼ 0.17). Not surprisingly, overall, patients with elevated platelets (4450 Â 10 9 l À1 ) had better MS than those with normal or low platelets (P ¼ 0.0002). Age, WBC count and hemoglobin did not have an impact on survival.
Next, we evaluated whether combined patient characteristics (that is, two variables combined, including age, WBC count, hemoglobin, platelet count, JAK2 mutation status and cytogenetic abnormalities) had an influence on survival. Overall, Table 1 Clinical, hematological, cytogenetic and molecular features of patients with MDS/MPD-U and RARS-T Letters to the Editor patients with JAK2 V617F mutation-associated thrombocytosis (MS not reached) had better survival than patients without JAK2 V617F mutation but with thrombocytosis (MS 80 months) or patients with low/normal platelets with (MS 32 months) or without the JAK2 V617F mutation (MS 10 months) (P ¼ 0.0008; Figure 1b ). Other combinations of variables had no impact on survival. Finally, patients with RARS-T had a significantly longer survival than those with myelodysplastic syndrome patients with RA ± RS (MS 55 months; P ¼ 0.01), but shorter than that of patients with essential thrombocythemia (ET; MS not reached; P ¼ 0.03, Figure 1c ) in our institution.
MDS/MPD-U RARS-T P-value
Several observations were made in this study. First, RARS-T and MDS/MPD-U are rare diseases, with only 16 and 28 patients, respectively, identified in our database (1150 MPD and 896 RA ± RS patients) over a period of approximately 20 years. This is similar to those published by other studies from large databases. 5 Second, we demonstrated better prognosis of patients with RARS-T as compared to those with MDS/MPD-U, even when accounting for an increased proportion of patients with abnormal cytogenetics in the MDS/MPD-U group. It was reported by Streeter et al. 7 that patients with idiopathic sideroblastic anemia and thrombocytosis have a decreased likelihood of leukemic transformation; however, the disease entity was not well defined as RARS-T. Two recent studies have explored survival in patients with RARS-T. 5, 8 In one study, 8 the authors identified 16 patients with RARS-T with MS of 71 months, comparable with patients with RARS, but less favorable than patients with ET. Similarly, the other study 5 reported an MS of 88 months, 44 months (P ¼ 0.09) and not reached (P ¼ 0.046) for RARS-T, MDS/MPD-U and ET patients, respectively. Our results are in keeping with the above studies, since we demonstrate that among patients with diploid cytogenetics, patients with RARS-T have better survival than patients with MDS/MPD-U. Third, we have found a high incidence of JAK2 V617F mutation in patients with both RARS-T and MDS/MPD-U that, when associated with thrombocytosis, confers a better prognosis in these patients. These results need to be confirmed in larger studies.
In conclusion, we have defined the prevalence of V617F in a well-defined cohort of RARS-T and MDS/MPD-U patients and determined its clinical correlates in each of these rare WHO myeloid subcategories. We confirm that RARS-T represents a unique subgroup of patients with better prognosis and longer overall survival, thus justifying their separate categorization. Our study suggests that the presence of thrombocytosis in these diseases may be more important than the presence of JAK2 V617F mutation but that patients with the presence of both the characteristics may have the most favorable prognosis. 
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